Literature DB >> 15086382

Protective effect of exogenous recombinant mouse interferon-gamma and tumour necrosis factor-alpha on ectromelia virus infection in susceptible BALB/c mice.

A V Atrasheuskaya1, E K Bukin, T M Fredeking, G M Ignatyev.   

Abstract

The resistance to mousepox is correlated with the production of type I cytokines: interleukin (IL)-2, IL-12, interferon (IFN)-gamma and tumour necrosis factor (TNF)-alpha. We intend to describe the modulation of generalized ectromelia virus (EV) infection with exogenous administration of mrIFN-gamma and mrTNF-alpha separately and in combination using susceptible BALB/c mice. The treatment schemes presented resulted in the localization of the generalized EV infection and its development into non-fatal sloughing of the infected limb. This was accompanied by low virus titres in the treated mice due to control of systemic virus replication and virus clearance. The balance of type I versus type II cytokines was dominated by a type I response in the treated groups. The group treated with the combination of IFN-gamma and TNF-alpha exhibited the best survival with Th1-dominant (IFN-gamma and IL-12) cytokine profiles, whereas the TNF-alpha-treated group of mice was less successful in clearance of virus and demonstrated the lowest survival rate. The successful cytokine treatment schemes in this orthopoxvirus model system may have important implications in the treatment of viral diseases in humans and, in particular, of variola virus infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15086382      PMCID: PMC1809029          DOI: 10.1111/j.1365-2249.2004.02460.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  Interferon gamma (IFNgamma ) and tumor necrosis factor alpha synergism in ME-180 cervical cancer cell apoptosis and necrosis. IFNgamma inhibits cytoprotective NF-kappa B through STAT1/IRF-1 pathways.

Authors:  K Suk; I Chang; Y H Kim; S Kim; J Y Kim; H Kim; M S Lee
Journal:  J Biol Chem       Date:  2001-01-18       Impact factor: 5.157

2.  Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox.

Authors:  R J Jackson; A J Ramsay; C D Christensen; S Beaton; D F Hall; I A Ramshaw
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  Serological detection of ectromelia virus antibody.

Authors:  M J Collins; R L Peters; J C Parker
Journal:  Lab Anim Sci       Date:  1981-10

4.  Th1/Th2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection.

Authors:  S Sobue; T Nomura; T Ishikawa; S Ito; K Saso; H Ohara; T Joh; M Itoh; S Kakumu
Journal:  J Gastroenterol       Date:  2001-08       Impact factor: 7.527

5.  Inhibition of interferons by ectromelia virus.

Authors:  Vincent P Smith; Antonio Alcami
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

6.  Analysis of constitutive cytokine expression by pigs infected in-utero with porcine reproductive and respiratory syndrome virus.

Authors:  W-H Feng; M B Tompkins; J-S Xu; H-X Zhang; M B McCaw
Journal:  Vet Immunol Immunopathol       Date:  2003-07-15       Impact factor: 2.046

7.  Immunological changes in patients with primary osteoarthritis of the hip after total joint replacement.

Authors:  Donatella Granchi; Lucia Savarino; Gabriela Ciapetti; Elisabetta Cenni; Roberto Rotini; Michele Mieti; Nicola Baldini; Armando Giunti
Journal:  J Bone Joint Surg Br       Date:  2003-07

8.  Combined protective effects on interferon and interferon induction on herpes simplex and ectromelia virus infections in mice.

Authors:  J Imanishi; M Matsubara; C J Won; H Nomura; T Kishida
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

9.  Evaluation of an enzyme-linked immunosorbent assay for the detection of ectromelia (mousepox) antibody.

Authors:  R M Buller; P N Bhatt; G D Wallace
Journal:  J Clin Microbiol       Date:  1983-11       Impact factor: 5.948

10.  Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons.

Authors:  G H Wong; D V Goeddel
Journal:  Nature       Date:  1986 Oct 30-Nov 5       Impact factor: 49.962

View more
  5 in total

1.  Gamma interferon and monophosphoryl lipid A-trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine.

Authors:  Avi-Hai Hovav; Yolanta Fishman; Herve Bercovier
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

2.  Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.

Authors:  Scott Parker; Jill Schriewer; Christina Oberle; Alice Robertson; Randall Lanier; George Painter; R Mark Buller
Journal:  Antivir Ther       Date:  2008

3.  CD8+ T cell-derived IFN-γ prevents infection by a second heterologous virus.

Authors:  Laura Valentine; Rashaun Potts; Mary Premenko-Lanier
Journal:  J Immunol       Date:  2012-11-07       Impact factor: 5.422

4.  Therapeutic and prophylactic drugs to treat orthopoxvirus infections.

Authors:  Scott Parker; Lauren Handley; R Mark Buller
Journal:  Future Virol       Date:  2008-11       Impact factor: 1.831

5.  Chemokines cooperate with TNF to provide protective anti-viral immunity and to enhance inflammation.

Authors:  Alí Alejo; M Begoña Ruiz-Argüello; Sergio M Pontejo; María Del Mar Fernández de Marco; Margarida Saraiva; Bruno Hernáez; Antonio Alcamí
Journal:  Nat Commun       Date:  2018-05-03       Impact factor: 17.694

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.